DARPP-32 Phosphorylation
The different phosphorylation sites on DARPP-32 are shown below, along with the respective kinases. To view to role of DARPP-32 in dopamine signaling, click on each of the dopamine receptor families below to see the signaling pathways activated by receptors in that family.
Nuclear
Export
Nuclear
Export
Receptor Family
Signaling
Receptor Family
Signaling
Dopamine D5 R/DRD5
Dopamine D1 and D5 Receptor Agonists
Dopamine D1 and D5 Receptor Antagonists
Dopamine Receptor Ligands
Non-selective Dopamine Receptor Agonists
Non-selective Dopamine Receptor Antagonists
Non-selective Dopamine Receptor Products
Additional Dopaminergic-related Products
Dopaminergic-related Inhibitors
Caged Compounds
Receptor Family
Signaling
Receptor Family
Signaling
Dopamine D2 Receptor Agonists
Dopamine D2 Receptor Antagonists
Dopamine D2 Receptor Modulators
Dopamine D3 R/DRD3
Dopamine D3 Receptor Agonists
Dopamine D3 Receptor Antagonists
Dopamine D4 Receptor Agonists
Dopamine D4 Receptor Antagonists
Dopamine D4 Receptor Ligands
Dopamine Receptor Ligands
Non-selective Dopamine Receptor Agonists
Non-selective Dopamine Receptor Antagonists
Non-selective Dopamine Receptor Products
Additional Dopaminergic-related Products
Dopaminergic-related Inhibitors
Caged Compounds
Signaling
Signaling
Signaling
Signaling
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Dopamine- and cAMP-Regulated Phosphoprotein, Mr 32 kDa (DARPP-32), a member of the protein phosphatase inhibitor 1 family, is a cytosolic protein that is selectively enriched in neostriatal medium spiny neurons. Traditionally, DARPP-32 has been considered a major dopamine (DA)-centered signaling molecule as it is needed for DA to exert most of its effects. DARPP-32 has been shown to function as either a kinase or phosphatase inhibitor, depending upon its phosphorylation state. DARPP-32, when phosphorylated at Thr34, acts as a potent inhibitor of Protein Phosphatase 1 (PP1). DA, acting through D1-like receptors, stimulates Protein Kinase A (PKA)-mediated phosphorylation of DARPP-32 at Thr34. However, DA binding to D2-like receptors will reduce DARPP-32 Thr34 phosphorylation by inhibiting PKA and activating the protein phosphatase Calcineurin. Phosphorylation of DARPP-32 at Thr34 is also facilitated by the phosphorylation of two serine residues, Ser97 and Ser130, which are phosphorylated by Casein Kinase 2 (CK2) and CK1, respectively. Phosphorylated Ser97 increases the rate of PKA-mediated Thr34 phosphorylation, and phosphorylated Ser130 decreases the rate at which Calcineurin dephosphorylates phosphorylated Thr34. By contrast, DARPP-32 will act as kinase inhibitor when phosphorylated at Thr75. Cyclin-Dependent-Like Kinase 5 (CDK5) phosphorylates DARPP-32 at Thr75, converting it into an inhibitor of PKA, reducing the ability of PKA to phosphorylate it substrates including DARPP-32 at Thr34. In addition to DA, several other neurotransmitters that regulate the excitability of dopaminoceptive neurons, such as glutamate, GABA, opiates, and adenosine, also signal through DARPP-32 in medium spiny neurons. The convergence of a large number of signaling pathways onto DARPP-32 in these neurons suggest that this molecule is important for integrating the vast amount of information that enters the neostriatum and ensuring that a logical neural response is produced.
